Want to see REGN full AI Analyst Report?

Regeneron (REGN) Stock Forecast & Price Target

5,235 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

15 Buy

6 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$814.81

▲(8.56% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $814.81 with a high forecast of $995.00 and a low forecast of $641.00. The average price target represents a 8.56% change from the last price of $750.57.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"530":"$530","763":"$763","996":"$996","646.5":"$646.5","879.5":"$879.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$995.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":814.8095238095237,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$814.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":641,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$641.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[530,646.5,763,879.5,996],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,624.72,653.203076923077,681.6861538461538,710.1692307692308,738.6523076923077,767.1353846153846,795.6184615384616,824.1015384615384,852.5846153846154,881.0676923076924,909.5507692307692,938.0338461538462,966.5169230769231,{"y":995,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,624.72,639.342271062271,653.9645421245422,668.5868131868132,683.2090842490843,697.8313553113553,712.4536263736263,727.0758974358974,741.6981684981685,756.3204395604396,770.9427106227106,785.5649816849816,800.1872527472527,{"y":814.8095238095237,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,624.72,625.9723076923077,627.2246153846154,628.4769230769231,629.7292307692308,630.9815384615384,632.2338461538461,633.4861538461539,634.7384615384616,635.9907692307693,637.243076923077,638.4953846153846,639.7476923076923,{"y":641,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":531.994,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":555.824,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":578.412,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":597.576,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":649.232,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":748.091,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":769.792,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":752.988,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":789.63,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":776.09,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":700.373,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":600.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":624.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$995.00

Average Price Target$814.81

Lowest Price Target$641.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

$700

Hold

-6.74%

Downside

Reiterated

07/15/26

Regeneron (REGN) Gets a Hold from Citi

Tazeen Ahmad

Bank of America Securities

$860→$856

Buy

14.05%

Upside

Reiterated

07/13/26

Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential

Evan Seigerman

BMO Capital

$730

Buy

-2.74%

Downside

Reiterated

07/13/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and InMode (NASDAQ: INMD)

Biren Amin

Piper Sandler

$854

Buy

13.78%

Upside

Assigned

07/09/26

Regeneron price target lowered to $854 from $855 at Piper SandlerRegeneron price target lowered to $854 from $855 at Piper Sandler

Terence Flynn

Morgan Stanley

$788→$730

Hold

-2.74%

Downside

Reiterated

07/08/26

Regeneron price target lowered to $730 from $788 at Morgan StanleyRegeneron price target lowered to $730 from $788 at Morgan Stanley

Mohit Bansal

Wells Fargo

$700

Hold

-6.74%

Downside

Assigned

07/08/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Newron Pharmaceuticals SpA (Other OTC: NWPHF) and Boston Scientific (NYSE: BSX)

Gregory Renza

Truist Financial

$778→$769

Buy

2.46%

Upside

Reiterated

07/07/26

Regeneron price target lowered to $769 from $778 at TruistRegeneron price target lowered to $769 from $778 at Truist

Brian Abrahams

RBC Capital

$707→$696

Hold

-7.27%

Downside

Reiterated

07/07/26

Regeneron price target lowered to $696 from $707 at RBC CapitalRegeneron price target lowered to $696 from $707 at RBC Capital

Rajesh Kumar

HSBC

$990→$800

Buy

6.59%

Upside

Reiterated

07/06/26

Regeneron price target lowered to $800 from $990 at HSBCRegeneron price target lowered to $800 from $990 at HSBC

Carter Gould

Cantor Fitzgerald

$785→$750

Buy

-0.08%

Downside

Reiterated

07/06/26

Regeneron price target lowered to $750 from $785 at Cantor FitzgeraldRegeneron price target lowered to $750 from $785 at Cantor Fitzgerald

Louise Chen

Scotiabank

$770

Hold

2.59%

Upside

Reiterated

07/01/26

Analysts Conflicted on These Healthcare Names: Alumis Inc. (NASDAQ: ALMS), Glaukos (NYSE: GKOS) and Regeneron (NASDAQ: REGN)

John Newman

Canaccord Genuity

$1,057→$875

Buy

16.58%

Upside

Reiterated

05/19/26

Regeneron price target lowered to $875 from $1,057 at CanaccordRegeneron price target lowered to $875 from $1,057 at Canaccord

David Risinger

Leerink Partners

$792→$641

Hold

-14.60%

Downside

Downgraded

05/18/26

Regeneron downgraded to Market Perform from Outperform at LeerinkRegeneron downgraded to Market Perform from Outperform at Leerink

Cory Kasimov

Evercore ISI

$875→$825

Buy

9.92%

Upside

Reiterated

05/18/26

Regeneron price target lowered to $825 from $875 at Evercore ISIRegeneron price target lowered to $825 from $875 at Evercore ISI

Salveen Richter

Goldman Sachs

$968

Buy

28.97%

Upside

Reiterated

05/18/26

Regeneron: Buy Rating and $968 Price Target Reaffirmed Despite Fi Anlimab Setback, Backed by Robust Pipeline and IP Extensions

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

$700

Hold

-6.74%

Downside

Reiterated

07/15/26

Regeneron (REGN) Gets a Hold from Citi

Tazeen Ahmad

Bank of America Securities

$860→$856

Buy

14.05%

Upside

Reiterated

07/13/26

Regeneron: Buy Rating Reaffirmed as Analyst Trims Eylea HD Forecasts and Lowers Price Target to $856 on Pipeline-Driven Upside Potential

Evan Seigerman

BMO Capital

$730

Buy

-2.74%

Downside

Reiterated

07/13/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and InMode (NASDAQ: INMD)

Biren Amin

Piper Sandler

$854

Buy

13.78%

Upside

Assigned

07/09/26

Regeneron price target lowered to $854 from $855 at Piper SandlerRegeneron price target lowered to $854 from $855 at Piper Sandler

Terence Flynn

Morgan Stanley

$788→$730

Hold

-2.74%

Downside

Reiterated

07/08/26

Regeneron price target lowered to $730 from $788 at Morgan StanleyRegeneron price target lowered to $730 from $788 at Morgan Stanley

Mohit Bansal

Wells Fargo

$700

Hold

-6.74%

Downside

Assigned

07/08/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN), Newron Pharmaceuticals SpA (Other OTC: NWPHF) and Boston Scientific (NYSE: BSX)

Gregory Renza

Truist Financial

$778→$769

Buy

2.46%

Upside

Reiterated

07/07/26

Regeneron price target lowered to $769 from $778 at TruistRegeneron price target lowered to $769 from $778 at Truist

Brian Abrahams

RBC Capital

$707→$696

Hold

-7.27%

Downside

Reiterated

07/07/26

Regeneron price target lowered to $696 from $707 at RBC CapitalRegeneron price target lowered to $696 from $707 at RBC Capital

Rajesh Kumar

HSBC

$990→$800

Buy

6.59%

Upside

Reiterated

07/06/26

Regeneron price target lowered to $800 from $990 at HSBCRegeneron price target lowered to $800 from $990 at HSBC

Carter Gould

Cantor Fitzgerald

$785→$750

Buy

-0.08%

Downside

Reiterated

07/06/26

Regeneron price target lowered to $750 from $785 at Cantor FitzgeraldRegeneron price target lowered to $750 from $785 at Cantor Fitzgerald

Louise Chen

Scotiabank

$770

Hold

2.59%

Upside

Reiterated

07/01/26

Analysts Conflicted on These Healthcare Names: Alumis Inc. (NASDAQ: ALMS), Glaukos (NYSE: GKOS) and Regeneron (NASDAQ: REGN)

John Newman

Canaccord Genuity

$1,057→$875

Buy

16.58%

Upside

Reiterated

05/19/26

Regeneron price target lowered to $875 from $1,057 at CanaccordRegeneron price target lowered to $875 from $1,057 at Canaccord

David Risinger

Leerink Partners

$792→$641

Hold

-14.60%

Downside

Downgraded

05/18/26

Regeneron downgraded to Market Perform from Outperform at LeerinkRegeneron downgraded to Market Perform from Outperform at Leerink

Cory Kasimov

Evercore ISI

$875→$825

Buy

9.92%

Upside

Reiterated

05/18/26

Regeneron price target lowered to $825 from $875 at Evercore ISIRegeneron price target lowered to $825 from $875 at Evercore ISI

Salveen Richter

Goldman Sachs

$968

Buy

28.97%

Upside

Reiterated

05/18/26

Regeneron: Buy Rating and $968 Price Target Reaffirmed Despite Fi Anlimab Setback, Backed by Robust Pipeline and IP Extensions

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TARAProtara Therapeutics

BKDBrookdale Senior Living

EYPTEyePoint Pharmaceuticals

ZVRAZevra Therapeutics

DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months

Yatin SunejaGuggenheim

Success Rate

9/14 ratings generated profit

Average Return

+3.11%

Copying Yatin Suneja's trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +3.11% per trade.

1 Year

Yatin SunejaGuggenheim

Success Rate

11/14 ratings generated profit

Average Return

+17.82%

Copying Yatin Suneja's trades and holding each position for 1 Year would result in 78.57% of your transactions generating a profit, with an average return of +17.82% per trade.

2 Years

Yatin SunejaGuggenheim

Success Rate

8/14 ratings generated profit

Average Return

+9.56%

Copying Yatin Suneja's trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +9.56% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 25 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. REGN average Analyst price target in the past 3 months is 814.81.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $10.36 with a range of $7.64 to $12.33. The previous quarter’s EPS was $9.47. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.81B with a range of $3.54B to $4.18B. The previous quarter’s sales results were $3.61B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 814.81.

What is REGN’s upside potential, based on the analysts’ average price target?

Regeneron Pharmaceuticals has 8.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron Pharmaceuticals has a consensus rating of Moderate Buy which is based on 15 buy ratings, 6 hold ratings and 0 sell ratings.

What is Regeneron Pharmaceuticals’s price target?

The average price target for Regeneron Pharmaceuticals is 814.81. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $995.00 ,the lowest forecast is $641.00. The average price target represents 8.56% Increase from the current price of $750.57.

What do analysts say about Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Detailed List of Analyst Forecasts